Ajanta Pharma Reports Robust Q2 FY'27 Results with PAT Surging 49% YoY
Ajanta Pharma Ltd 路 Outcome 路 30 Oct 2026, 6:32 pm
Ajanta Pharma Reports Robust Q2 FY'27 Results with PAT Surging 49% YoY Ajanta Pharma posted a strong Q2 FY'27 performance, with consolidated revenue rising 33% YoY to Rs. 1,794 cr. and net profit surging 49% YoY to Rs. 388 cr. Adjusted EBITDA expanded 47% YoY to Rs. 543 cr., achieving a 30% margin. Growth was driven by Branded Generics rising 23% YoY to Rs. 1,182 cr., US Generics surging 41% YoY to Rs. 484 cr., and Africa Institution jumping 259% YoY. For H1 FY'27, revenue reached Rs. 3,420 cr. with healthy ROCE at 41% and ROE at 31%.
Original exchange filing (PDF)
More announcements from Ajanta Pharma Ltd
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 18, 2026 for Aayush Agrawal, .... 路 18 Nov 2026
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 16, 2026 for Aayush Agrawal, .... 路 17 Nov 2026
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 09, 2026 for Aayush Agrawal, .... 路 09 Nov 2026
- Pls find enclosed Earnings Call Written Transcript 路 04 Nov 2026
- Pls find enclosed Audio recording of Earnings Call 路 30 Oct 2026
- Pls find enclosed results for the quarter ended 30.09.2026. 路 30 Oct 2026
- Pls find enclosed Financial Results for the quarter ended 30.09.2026. 路 30 Oct 2026
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee .... 路 21 Oct 2026
